RecruitingNCT05400239

SOTO: Treatment Sensitivity of Organoids to Predict Treatment Outcome

SOTO Study: Prospective Study to Correlate the Treatment Sensitivity of Patient-derived Organoids With Clinical Outcomes in Head and Neck Squamous Cell Carcinoma (HNSCC) Patients


Sponsor

Guy's and St Thomas' NHS Foundation Trust

Enrollment

60 participants

Start Date

Jun 1, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

In this study, we aim to assess whether Patient Derived Organoids can be used to predict treatment sensitivity in HNSCC patients.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is growing small copies of patients' tumors in the lab (called organoids) to test which treatments are most likely to work — potentially helping doctors choose the best therapy for each individual person with head and neck cancer. **You may be eligible if...** - You are over 18 years old - You have been diagnosed with squamous cell carcinoma of the head and neck (including oral cavity, throat, sinuses, voice box, or lower throat) - You are receiving treatment with either surgery or radiation, or have recurring or metastatic disease **You may NOT be eligible if...** - You are unable to give informed consent (for example, due to a cognitive or intellectual disability) - You are under 18 years old Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Guys Hospital

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05400239


Related Trials